Aemetis (NASDAQ:AMTX) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS

Key Points

• Missed estimates: Aemetis reported Q1 EPS of ($0.33) vs. the consensus ($0.27) and revenue of $54.62M (vs. $66.70M expected), and the stock fell about 3.7% to $3.12 on the news.
• Operational improvement: Management highlighted a 27% YoY revenue increase, a return to positive gross profit ($2.8M) and a ~60% cut in operating loss, with the Keyes MVR project under construction (expected to displace ~80% of plant natural gas and add roughly $32M of annual cash flow) and India biodiesel recovery supporting a planned Universal Biofuels IPO.
• Financing and 45Z dependency: Large-scale projects, including the 80M‑gallon RD/SAF facility, have permits and market interest but face near‑term uncertainty because final economics and funding hinge on the DOE’s updated 45Z CF‑GREET calculator and securing long‑term financing.

Aemetis (NASDAQ:AMTX - Get Free Report) issued its earnings results on Thursday. The specialty chemicals company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.06), FiscalAI reports. The company had revenue of $54.62 million during the quarter, compared to analyst estimates of $66.70 million.

Here are the key takeaways from Aemetis' conference call:

• Financial inflection point: Q1 revenue rose 27% YoY to $54.6M, the company returned to positive gross profit ($2.8M) and cut operating loss ~60%, signaling improved underlying margins across all segments.
• LCFS pathway approvals: CARB approved 7 new RNG pathways at an average CI of -380 (vs -150 default) with 6 more nearing approval, which materially increases LCFS credit generation per MMBtu and should boost revenue as production scales.
• Capital projects advancing: Dairy pretreatment skids delivered under a $27M contract and the $40M MVR project at Keyes is under construction with major equipment on-site; management expects MVR commissioning later this year to displace ~80% of plant natural gas and add roughly $32M of annual cash flow.
• India operations & IPO plan: Q1 India biodiesel revenue rebounded to $10.5M, management has retained advisors for an IPO of Universal Biofuels and expects improved, cost‑plus contract pricing and higher utilization to support the offering and expansion funding.
• Financing and 45Z dependency: Large projects (notably the 80M gallon RD/SAF facility) have permits and market interest but financing timing and final economics hinge on the DOE publishing the updated 45Z CF‑GREET calculator and securing long‑term financing, creating near‑term uncertainty.

Aemetis Stock Down 3.7%

Shares of Aemetis stock traded down $0.12 during trading hours on Thursday, hitting $3.12. 3,111,094 shares of the company's stock traded hands, compared to its average volume of 1,790,618. The stock has a 50 day simple moving average of $2.49 and a 200-day simple moving average of $1.98. The company has a market cap of $212.63 million, a PE ratio of -2.35 and a beta of 1.46. Aemetis has a twelve month low of $1.22 and a twelve month high of $3.80.

Institutional Trading of Aemetis

Several large investors have recently modified their holdings of the business. Creative Planning acquired a new stake in shares of Aemetis during the second quarter valued at about $30,000. Bank of America Corp DE grew its stake in shares of Aemetis by 62.6% during the third quarter. Bank of America Corp DE now owns 38,526 shares of the specialty chemicals company's stock valued at $87,000 after acquiring an additional 14,836 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Aemetis by 206.7% during the second quarter. Tower Research Capital LLC TRC now owns 22,962 shares of the specialty chemicals company's stock valued at $57,000 after acquiring an additional 15,474 shares in the last quarter. Engineers Gate Manager LP acquired a new stake in shares of Aemetis during the second quarter valued at about $42,000. Finally, Centiva Capital LP acquired a new stake in shares of Aemetis during the third quarter valued at about $39,000. 27.02% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on AMTX. Weiss Ratings reiterated a "sell (e+)" rating on shares of Aemetis in a report on Monday, April 20th. Wall Street Zen upgraded Aemetis from a "sell" rating to a "hold" rating in a report on Sunday, March 22nd. Loop Capital set a $1.75 price target on Aemetis in a report on Thursday, March 12th. Finally, Ascendiant Capital Markets increased their price target on Aemetis from $20.00 to $21.00 and gave the company a "buy" rating in a report on Wednesday, April 8th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $8.58.

Aemetis Company Profile

Aemetis, Inc, headquartered in Cupertino, California, is a renewable fuels and renewable natural gas producer dedicated to decarbonizing the transportation sector. The company operates two primary business segments: Aemetis Advanced Fuels, which manufactures ethanol, biodiesel and sustainable aviation fuel using patented carbon capture and separation technology; and Aemetis RNG, which develops dairy-based renewable natural gas projects in California for pipeline injection and transportation use.

Since its incorporation in 2006, Aemetis has expanded its production footprint through organic growth and strategic acquisitions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.